In a GxP environment, every system that creates, processes, or stores regulated data has to stand up to inspection. Entourage delivers risk-based CSV programmes aligned to GAMP 5, 21 CFR Part 11, and EU Annex 11, so your systems are compliant, your data is trustworthy, and your inspections are passed.
Senior CSV expertise on every engagement. No off-the-shelf templates.
Pharmaceutical companies operate dozens to hundreds of computerised systems touching GxP data. Without a structured, risk-based validation approach, each system becomes a potential observation: untraceable data, missing audit trails, unvalidated changes, no evidence of testing. Regulators have sharply increased scrutiny of data integrity across all GxP systems, from lab instruments to cloud-hosted SaaS.
GxP-critical systems are undocumented, unclassified, and inconsistently managed across the site.
Missing, incomplete, or manipulable audit trails are the single most common cause of FDA warning letters and EMA findings.
Validation responsibility stays with the pharma company, yet most lack a structured approach for vendor-managed systems.
Updates, patches, and configuration changes without validated change control compound risk over time.
We classify every system by GAMP 5 category and criticality, then scale the validation effort to match. No over-validation. No gaps.
Qualification, not validation. Operating systems, networks, and platforms verified as fit for purpose.
Off-the-shelf software used as supplied. Standard IQ/OQ against intended use.
LIMS, MES, ERP and similar. Full IQ/OQ/PQ covering configuration against requirements.
Custom-developed systems. Full SDLC documentation across the build lifecycle.
Adaptive and machine-learning systems. Continuous validation plus change management.
We execute systematic validation workflows that ensure inspection readiness and system safety at every stage.
Establish complete visibility of every GxP computerised system and a defensible validation rationale.
Build the full GxP inventory, classify by GAMP 5 category, and author the Validation Master Plan (VMP). Full visibility, defensible rationale, and inspection-ready from day one.
Prove each system is fit for its intended GxP use through documented, traceable testing.
Execute IQ/OQ/PQ and UAT with URS, FS, DS, configuration specs, protocols, and summary reports scaled to category. Traceable validation packages and no open deviations at go-live.
Design data integrity into the validated state rather than bolting it on afterwards.
Run ALCOA+ assessment, audit trail review, access control, e-signature, and backup/recovery as integral protocol components. Zero data integrity observations and demonstrable ALCOA+ compliance.
Keep systems in a validated state long after go-live and prevent compliance drift.
Implement change control, periodic review schedules, validated-state registers, and post-validation support. A maintained validated state with no compliance drift between inspections.
We validate computerised systems across your entire operations, ensuring absolute compliance.
Our validation approaches align directly with the core regulations that auditors look for.
The risk-based framework for computerised system validation across the GxP lifecycle.
FDA requirements for electronic records and electronic signatures.
Computerised systems in EU GMP: supplier assessment, backup, and business continuity.
FDA (2018) and EMA (2016) data integrity guidance: Attributable, Legible, Contemporaneous, Original, Accurate, plus Complete, Consistent, Enduring, and Available.
A real, anonymised remediation case study showing how structural sequence outperforms ad-hoc actions.
Follow-up inspection result after a 12-week remediation cycle.
A mid-size pharma manufacturer faced Warning Letter risk after an FDA inspection found data integrity gaps across multiple GxP systems, with no validated change control and incomplete audit trails. Unvalidated changes had been made to LIMS and MES without impact assessment, audit trails were disabled or incomplete on three critical lab data systems, and there was no GxP inventory, no VMP, and no consistent validation approach.
Full GxP inventory across manufacturing, QC, and QA. Risk-based GAMP 5 classification with a prioritised remediation roadmap. Retrospective and prospective validation of LIMS, CDS, MES, QMS, and EBR. ALCOA+ remediation across the affected systems.
IQ/OQ/PQ for all priority systems within a 12-week remediation window. Validated change control implemented, with retrospective impact assessments. UAT with key users. Full documentation per system (URS, FS, DS, configuration, plan, summary) and a traceability matrix, with zero open deviations at go-live.
Audit trails enabled with formal review procedures. Access control and e-signature validation against 21 CFR Part 11 and Annex 11.
VMP and GxP register embedded as site governance. First periodic review cycle completed. Training delivered to IT, QA, and system owners.
The follow-up FDA inspection closed with zero data integrity observations. All systems in a validated state, audit trails operational, and governance embedded in site procedures.
Whether you are building a CSV programme from scratch, facing a data integrity finding, preparing for a system implementation, or approaching an inspection, we will assess your validation landscape together.


Senior CSV expertise on every engagement. No off-the-shelf templates.